JOSEPH POLLINO: Open Payments
NPI 1235610635 · GARDNERVILLE, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$498 in 19 payments from 12 companies in 2025. Trend: 2023 $95 · 2024 $48 · 2025 $498
Food & beverage: $498
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 1 | $143 |
| Astellas Pharma US Inc | 3 | $58 |
| ABBVIE INC. | 3 | $58 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| PFIZER INC. | 2 | $33 |
| BioCryst US Sales Co., LLC | 1 | $27 |
| GlaxoSmithKline, LLC. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| MAYNE PHARMA COMMERCIAL LLC | 1 | $23 |
Products named: FARXIGA, Veozah, JOURNAVX, UBRELVY, CAPLYTA, ORLADEYO, TRELEGY ELLIPTA, TAKHZYRO.
Industry payments across NV — which companies pay providers there.
